In femoro-popliteal artery (FPA) disease, Bare-Nitinol Stent (BNS) and Paclitaxel-coated balloon (PCB) improved outcomes as compared to Uncoated-Balloon (UCB) angioplasty. Nevertheless, the relative efficacy of BNS vs. PCB remains unknown, due to the lack of head-to-head comparisons. We performed an adjusted indirect comparison meta-analysis of randomized trials to evaluate outcomes of BNS versus PCB in FPA disease. Methods: A systematic literature search (PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, scientific session abstracts and relevant websites) through December 2011 was performed. Selected search words were: superficial-femoral artery, popliteal artery, angioplasty, self-expanding stent, nitinol-stent, bare-stent, drug-eluting balloon, paclitaxel-coated balloon, and randomized trial. Inclusion criteria were: randomized trial design, intention to treat analysis, Ն6-month follow-up (FU Boston Scientific, Marlborough, MA, 7 Boston Scientific Corporation, Marlborough, MA Background: ORION is a prospective, multicenter, single-arm, long-term safety and efficacy study of the Epic™ vascular self-expanding stent for the treatment of iliac artery lesions. Methods: Eligible patients had chronic, symptomatic iliac disease and received Յ2 stents for de novo/restenotic lesions in the common or external iliac arteries. Lesions were Յ13 cm in length with diameter stenosis Ն50%. Clinical, functional, hemodynamic, and duplex ultrasound follow-up was performed at 30 days and 9 and 12 months. Key endpoints evaluated at one year include primary, primary-assisted, and secondary patency, target lesion revascularization (TLR), stent thrombosis, amputation, assessment of the walking impairment questionnaire and ankle-brachial index (ABI). All deaths, revascularization, myocardial infarctions, amputations, and stent thromboses were adjudicated by an independent clinical events committee (CEC). Results: A total of 125 patients were enrolled in the study. Through 12 months, primary patency, primary-assisted patency, and secondary patency was achieved in 94.4% (119/126), 96.0% (121/126), and 97.6% (122/125) of treated lesions and 95.4% of patients remained free from TLR. Improvement in ABI by Ն0.1 was seen in 63.6% (84/132) of treated limbs. Three patients had stent thrombosis through 30 days and 2 patients died through 12 months. There were no amputations performed. Across the patient population, statistically significant improvements from baseline in walking distance (P Ͻ0.0001), walking speed (P Ͻ0.0001), and stair climbing (P Ͻ0.0001) were reported through 12 months.

